[Secondary prevention after myocardial infarction]

Area of Science:

• Cardiology
• Cardiovascular Medicine
• Internal Medicine

Context:

• Mortality from myocardial infarction has decreased due to reperfusion therapies and improved drug treatments.
• However, recurrent myocardial infarction, heart failure, arrhythmias, and sudden cardiac death remain significant concerns, particularly within the first two years post-event.
• Existing clinical guidelines for secondary prevention are not consistently implemented in practice.

Purpose:

• To emphasize the persistent risks following myocardial infarction and the critical need for effective secondary prevention strategies.
• To highlight the shared pathophysiological mechanisms of acute coronary syndromes and the importance of consistent secondary prevention approaches for all patient categories.
• To underscore the necessity of early risk stratification and adherence to established guidelines for managing persistent risk factors.

Summary:

• Patients with and without ST-elevation myocardial infarction share the same underlying atherosclerotic plaque rupture mechanism, necessitating uniform secondary prevention.
• Acute coronary syndromes increase the risk of adverse cardiovascular outcomes, requiring aggressive management of persistent risk factors like smoking, hypertension, obesity, hypercholesterolemia, and diabetes.
• Early risk stratification using various diagnostic tools is essential to identify residual myocardial ischemia and guide prognosis, which depends on left ventricular function and ischemia extent.

Impact:

• Implementing comprehensive secondary prevention, including risk factor modification (weight reduction, dietary changes, smoking cessation, regular physical activity) and cardiac rehabilitation, can significantly improve exercise tolerance and cardiovascular outcomes.
• Addressing the gap between recommended guidelines and actual medical practice is vital for reducing long-term morbidity and mortality after myocardial infarction.
• Personalized risk assessment and tailored interventions are key to mitigating the ongoing risks associated with atherosclerotic cardiovascular disease.